

BÖLÜM 34

MALİGNİTELİ HASTALARIN PANDEMİ SÜRECİNDE SAĞLIK BAKIMI

Seda YILMAZ¹

1. GİRİŞ

COVID-19 pandemisi, tıbbi bakım da dahil olmak üzere günlük yaşamın tüm alanlarını etkilemiştir. Hem kanser, hem de aldıkları tedavilerden dolayı immunsuprese durumda olan hastalara, bu kriz sırasında bakım sağlamak zordur (1,2). Elektif operasyonların ertelenmesi, kemoterapi/radyoterapiye ulaşım ve devam kararındaki zorluklar, hastalığın ve uygulanan tedavilerin getirebileceği ek riskler hastalara bakımı zorlaştırmaktadır. Bu bölümde, pandemi süresince malignite tedavilerinin aksamasından kaynaklanan riskler ve sağlık hizmetlerinin uygun şekilde nasıl verilebileceği konuları ele alınacak, kanser bakımı önerileri incelenecektir (3-9).

2. İNSİDANS

Kanser hastalarında COVID-19 insidansı hakkında bilgilerin büyük bölümü Çin kaynaklı (1) olup; Wuhan' da yapılan bir çalışmada, COVID-19 hastalarının yaklaşık % 1 ila 2' sinde kanser saptanmıştır (10,13). Diğer taraftan, New York' da

COVID-19 nedeniyle hastanede yatan 5700 hastanın % 6' sının (14), Lombardiya' da COVID-19 nedeniyle yoğun bakım ünitesinde takip edilen hastaların % 8' inin aktif dönemde veya geçmişte kanser öyküsü olduğu saptanmıştır (15).

3. KLİNİK SEMPTOMLAR

Kanser olmayan popülasyonlarda olduğu gibi, kanser hastalarında da COVID-19' un klinik özellikleri genellikle ateş, kuru öksürük, nefes darlığı, titreme, kas ağrısı, baş ağrısı, boğaz ağrısı, titreme, ishal, tat/koku kaybıdır. Her ne kadar COVID-19 yaşlı insanlarda daha şiddetli ve ölümcül olsa da (16), kanser öyküsü olan kişiler yaştan bağımsız risk altındadır (17). Wuhan şehrinde yapılan bir çalışmada en sık görülen kanser türünün akciğer kanseri olduğu saptanmıştır. Klinik seyir açısından, hastaların yarısından fazlasında şiddetli hastalık izlenmiştir ve bilgisayarlı tomografide yamalı konsolidasyon bulgusunun olması daha yüksek oranda ciddi hastalık riski ile ilişkili bulunmuştur. Ayrıca son 14 gün içinde kemote-

¹ Uzm. Dr. Seda Yılmaz Sağlık Bilimleri Üniversitesi, Konya Eğitim ve Araştırma Hastanesi, Hematoloji Kliniği, dr46sedakurtulus@hotmail.com



KAYNAKLAR

1. Yu, Jing, et al. "SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China." *JAMA oncology* (2020).
2. Lewis, Mark A. "Between Scylla and Charybdis—oncologic decision making in the time of Covid-19." *New England Journal of Medicine* (2020).
3. American Society Of Clinical Oncology, et al. COVID-19 patient care information. American Society of Clinical Oncology Web site. 2020.
4. <https://www.cdc.gov/coronavirus/2019-ncov/healthcare-facilities/guidance-hcf.html> (Accessed on April 02, 2020).
5. <https://www.astro.org/Daily-Practice/COVID-19-Recommendations-and-Information/COVID-19-FAQs#q8> (Accessed on April 02, 2020).
6. <https://www.facs.org/covid-19> (Accessed on April 02, 2020).
7. <https://www.nccn.org/covid-19/default.aspx> (Accessed on April 16, 2020).
8. <https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic> (Accessed on April 16, 2020).
9. <https://www.surgonc.org/resources/covid-19-resources/>.
10. Zheng, R. S., et al. Report of cancer epidemiology in China, 2015. *Zhonghua zhong liu za zhi [Chinese journal of oncology]*, 2019, 41.1: 19-28.
11. Desai, Aakash, et al. "COVID-19 and cancer: lessons from a pooled meta-analysis." *JCO global oncology* 6 (2020).
12. Emami, Amir, et al. "Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis." *Archives of academic emergency medicine* 8.1 (2020).
13. Hu, Yong, et al. "Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis." *Journal of Clinical Virology* (2020): 104371.
14. Richardson, Safiya, et al. "Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area." *Jama* (2020).
15. Grasselli, Giacomo, et al. "Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy." *Jama* 323.16 (2020): 1574-1581.
16. Verity, Robert, et al. "Estimates of the severity of coronavirus disease 2019: a model-based analysis." *The Lancet infectious diseases* (2020).
17. Covid, C. D. C., et al. "Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020." *Morbidity and Mortality Weekly Report* 69.13 (2020): 382.
18. Zhang, L., et al. "Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China." *Annals of Oncology* (2020).
19. Huang, Chaolin, et al. "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China." *The lancet* 395.10223 (2020): 497-506.
20. Guan, Wei-jie, et al. "Clinical characteristics of coronavirus disease 2019 in China." *New England journal of medicine* 382.18 (2020): 1708-1720.
21. Wang, Dawei, et al. "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China." *Jama* 323.11 (2020): 1061-1069.
22. Liu, Wei, et al. "Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease." *Chinese medical journal* (2020).
23. Wang, Bolin, et al. "Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis." *Aging (Albany NY)* 12.7 (2020): 6049.
24. Dai, Mengyuan, et al. "Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak." *Cancer discovery* 10.6 (2020): 783-791.
25. Miyashita, Hirotaka, et al. "Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City." *Annals of Oncology* (2020).
26. Mehta, Vikas, et al. "Case fatality rate of cancer patients with COVID-19 in a New York hospital system." *Cancer discovery* (2020).
27. Falavigna, Maicon, et al. "Diretrizes para o Tratamento Farmacológico da COVID-19. Consenso da.
28. Ueda, Masumi, et al. "Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal." *Journal of the National Comprehensive Cancer Network* 1.aop (2020): 1-4.
29. Martínez-Cordero, Humberto, et al. "A proposal for early, multidisciplinary and goal-directed sequential treatment in SARS CoV2/COVID-19 infection requiring hospitalization and intensive care unit." *management* 21: 22.
30. George, Bhawana, et al. "Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas." *Cancers* 12.5 (2020): 1328.
31. Dinmohamed, Avinash G., et al. "Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands." *The Lancet Oncology* 21.6 (2020): 750-751.
32. Cinar, Pelin, et al. "Safety at the time of the COVID-19 pandemic: how to keep our oncology patients and healthcare workers safe." *Journal of the National Comprehensive Cancer Network* 1.aop (2020): 1-6.
33. Cancer Surgery and COVID19. *Annals of Surgical Oncology*, 1-4.
34. <https://covid19bilgi.saglik.gov.tr/tr/covid-19-pandemisinde-normallesme-doneminde--saglik-kurumlarinda-calisma-rehberi>
35. Marijnen, C. A. M., et al. "International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic." *Radiotherapy and Oncology* 148 (2020): 213-215.
36. Kutikov, Alexander, et al. "A war on two fronts: cancer care in the time of COVID-19." (2020).